FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

PT-141 Stack

Sexual Healthbeginner

79

synergie

79
Share
Pépétides

2

Moyenne journalière en mcg

1,850

Niveau

beginner

Ajouté

May 17, 2026

Aperçu

The PT-141 Stack combines the melanocortin-based sexual desire activation of PT-141 with oxytocin''s bonding and arousal enhancement — creating a protocol that addresses both the neurological desire component and the psychological intimacy component of sexual function. PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (under the brand name Vyleesi). Unlike PDE5 inhibitors (Viagra, Cialis) which work peripherally on blood flow, PT-141 works centrally — activating melanocortin receptors in the brain that regulate sexual desire and arousal in both men and women. It creates genuine motivation and desire rather than mechanical function, making it effective regardless of whether vascular issues are present. It is typically administered 45 minutes before sexual activity. Oxytocin — the "bonding hormone" — is naturally released during physical touch, orgasm, and social bonding. Intranasal oxytocin administration promotes feelings of closeness, trust, and emotional connection, enhancing the relational component of sexual experience. Research shows intranasal oxytocin improves sexual satisfaction, intimacy, and communication in couples. It is administered 15–30 minutes before activity for peak effect. The synergy is complementary: PT-141 addresses the neurological desire mechanism while oxytocin enhances the emotional and relational experience. For couples navigating desire or intimacy issues, this combination targets both the physiological and psychological components simultaneously. PT-141 is used sparingly (maximum 2 uses per week) to prevent receptor downregulation; oxytocin can be used more frequently without tolerance development.

Protocole de dose

PT-141 (Bremelanotide)

as needed (1-2x per week max)· subcutaneous

Lire plus sur PT-141 (Bremelanotide) →

1,750 mcg

par dose

Oxytocin

as needed· intranasal

Lire plus sur Oxytocin →

100 mcg

par dose

Objectifs & Preuves

Sexual desireArousalIntimacyBondingSexual function
Niveau d'évidence :Essai clinique humain

Avertissements

  • PT-141 can cause temporary nausea, flushing, and blood pressure changes. Do not use with PDE5 inhibitors. Oxytocin nasal sprays are not FDA-approved but widely compounded.

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.